Information date: 8 September 2026 — FDA explains that cosmetic status and claims depend on intended use: claims to treat disease or affect the structure or function of the body can place a product within drug requirements, regardless of a fashionable ingredient name. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
FDA explains that cosmetic status and claims depend on intended use: claims to treat disease or affect the structure or function of the body can place a product within drug requirements, regardless of a fashionable ingredient name.
For GHK-Cu, reviewers should separate chemical identity and purity, mechanistic or laboratory findings, formulation stability and delivery, finished-product testing, and the exact consumer-facing claim.
How the effect reaches operations
Copper binding and cell responses observed under controlled conditions do not show that a complex cream keeps the peptide intact, reaches the relevant site or produces the same endpoint during normal use.
Borrowing an ingredient paper for a finished product can ignore concentration, degradation, vehicle and comparator. Before-and-after images without controlled acquisition can exaggerate change.
For “GHK-Cu Product Claims Need Three Evidence Layers: Ingredient, Formulation and Finished Product”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
Allow cosmetic appearance claims only when the finished product and study support the wording. Do not convert pathway evidence into wound treatment, tissue regeneration or systemic benefit.
Implementation checklist
- Create an evidence table linking every claim to ingredient or finished-product data.
- Verify identity, stability, packaging and test conditions for the actual formulation.
- Remove or narrow claims that imply disease treatment or structural change without the required pathway.
- Assign one decision owner, one implementation owner and a dated review point for “GHK-Cu Product Claims Need Three Evidence Layers: Ingredient, Formulation and Finished Product”.
- For “GHK-Cu Product Claims Need Three Evidence Layers: Ingredient, Formulation and Finished Product”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “GHK-Cu Product Claims Need Three Evidence Layers: Ingredient, Formulation and Finished Product”.
Evidence and review
For “GHK-Cu Product Claims Need Three Evidence Layers: Ingredient, Formulation and Finished Product”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Create an evidence table linking every claim to ingredient or finished-product data.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Verify identity, stability, packaging and test conditions for the actual formulation.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Remove or narrow claims that imply disease treatment or structural change without the required pathway.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Counter-scenario and ownership
The review must also test the opposite of the expected outcome. If “Copper binding and cell responses observed under controlled conditions do not show that a complex cream keeps the peptide intact, reaches the relevant site or produces the same endpoint during normal use.”, the record should already identify who detects it, who can pause the process, and who communicates with affected people or authorities. Direct, current evidence about the studied product, population or transaction takes priority when it conflicts with a broad market statement. Keep both the approval reason and the rejection reason. Later evidence should reopen only the affected question, not trigger an unsupported rewrite of findings that still hold.
Limits of the conclusion
Regulatory classification varies by claim and jurisdiction. This is an evidence framework, not proof of safety, effectiveness or lawful marketing for a product.
